Joseph P Balthasar

List of Publications by Year
in descending order

70 papers	**3,421** citations	172457 **29** h-index	144013 **57** g-index
70 all docs	**70** docs citations	**70** times ranked	**2970** citing authors

#	Article	IF	Citations
1	Antibody Pharmacokinetics and Pharmacodynamics. Journal of Pharmaceutical Sciences, 2004, 93, 2645-2668.	3.3	804
2	Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. Journal of Pharmacokinetics and Pharmacodynamics, 2007, 34, 687-709.	1.8	295
3	Intravenous Immunoglobulin Mediates an Increase in Anti-Platelet Antibody Clearance via the FcRn Receptor. Thrombosis and Haemostasis, 2002, 88, 898-899.	3.4	143
4	Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. Journal of Pharmacokinetics and Pharmacodynamics, 2013, 40, 597-607.	1.8	123
5	Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood, 2002, 100, 2087-2093.	1.4	121
6	Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biology and Medicine, 2014, 11, 20-33.	3.0	109
7	Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibody. Journal of Pharmaceutical Sciences, 2010, 99, 1582-1600.	3.3	94
8	Evaluation of a Catenary PBPK Model for Predicting the In Vivo Disposition of mAbs Engineered for High-Affinity Binding to FcRn. AAPS Journal, 2012, 14, 850-859.	4.4	91
9	Investigation of the Influence of FcRn on the Distribution of IgG to the Brain. AAPS Journal, 2009, 11, 553-7.	4.4	88
10	High-Throughput Method Development for Sensitive, Accurate, and Reproducible Quantification of Therapeutic Monoclonal Antibodies in Tissues Using Orthogonal Array Optimization and Nano Liquid Chromatography/Selected Reaction Monitoring Mass Spectrometry. Analytical Chemistry, 2012, 84, 4373-4382.	6.5	66
11	Pharmacokinetic/Pharmacodynamic Modeling of the Effects of Intravenous Immunoglobulin on the Disposition of Antiplatelet Antibodies in a Rat Model of Immune Thrombocytopenia. Journal of Pharmaceutical Sciences, 2003, 92, 1206-1215.	3.3	64
12	Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies. Journal of Pharmacokinetics and Pharmacodynamics, 2016, 43, 427-446.	1.8	62
13	Effects of Calibration Approaches on the Accuracy for LC–MS Targeted Quantification of Therapeutic Protein. Analytical Chemistry, 2014, 86, 3575-3584.	6.5	56
14	Qualitative and quantitative characterization of protein biotherapeutics with liquid chromatography mass spectrometry. Mass Spectrometry Reviews, 2017, 36, 734-754.	5.4	56
15	Investigation of the Role of FcγR and FcRn in mAb Distribution to the Brain. Molecular Pharmaceutics, 2013, 10, 1505-1513.	4.6	54
16	Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thrombosis and Haemostasis, 2002, 88, 898-9.	3.4	53
17	Pharmacokinetic Effects of 4C9, An Anti-FcRn Antibody, in Rats: Implications for the Use of FcRn Inhibitors for the Treatment of Humoral Autoimmune and Alloimmune Conditions. Journal of Pharmaceutical Sciences, 2005, 94, 718-729.	3.3	51
18	Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development. Drug Metabolism and Pharmacokinetics, 2019, 34, 3-13.	2.2	51

#	Article	IF	Citations
19	Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy. Journal of Controlled Release, 2014, 194, 197-210.	9.9	49
20	The Capsular Polysaccharide of Acinetobacter baumannii Is an Obstacle for Therapeutic Passive Immunization Strategies. Infection and Immunity, 2017, 85, .	2.2	47
21	Understanding Inter-Individual Variability in Monoclonal Antibody Disposition. Antibodies, 2019, 8, 56.	2.5	46
22	Nano-scale liquid chromatography/mass spectrometry and on-the-fly orthogonal array optimization for quantification of therapeutic monoclonal antibodies and the application in preclinical analysis. Journal of Chromatography A, 2012, 1251, 63-73.	3.7	45
23	Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 683-710.	1.8	43
24	Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood, 2002, 100, 2087-93.	1.4	43
25	Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections. Antibodies, 2018, 7, 5.	2.5	42
26	Evaluation of Near Infrared Fluorescent Labeling of Monoclonal Antibodies as a Tool for Tissue Distribution<sup />. Drug Metabolism and Disposition, 2014, 42, 1906-1913.	3.3	41
27	Use of an Anti-Vascular Endothelial Growth Factor Antibody in a Pharmacokinetic Strategy to Increase the Efficacy of Intraperitoneal Chemotherapy. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 580-591.	2.5	38
28	Assessments of antibody biodistribution. Journal of Clinical Pharmacology, 2015, 55, S29-38.	2.0	32
29	Application of knockout mouse models to investigate the influence of FcÎ³R on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. International Journal of Pharmaceutics, 2012, 439, 8-16.	5.2	29
30	Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys. Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42, 527-540.	1.8	29
31	Sensitive, High-Throughput, and Robust Trapping-Micro-LC-MS Strategy for the Quantification of Biomarkers and Antibody Biotherapeutics. Analytical Chemistry, 2018, 90, 1870-1880.	6.5	29
32	Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer. Cancer Chemotherapy and Pharmacology, 2011, 68, 951-958.	2.3	27
33	Application of Pharmacokineticâ€"Pharmacodynamic Modeling to Predict the Kinetic and Dynamic Effects of Anti-Methotrexate Antibodies in Mice. Journal of Pharmaceutical Sciences, 2003, 92, 1665-1676.	3.3	26
34	Pharmacokinetic mAbâ€"mAb Interaction: Anti-VEGF mAb Decreases the Distribution of Anti-CEA mAb into Colorectal Tumor Xenografts. AAPS Journal, 2012, 14, 445-455.	4.4	26
35	Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 Efficacy. Cancer Research, 2021, 81, 4145-4154.	0.9	26
36	Inverse Targeting of Peritoneal Tumors: Selective Alteration of the Disposition of Methotrexate Through the Use of Anti-Methotrexate Antibodies and Antibody Fragments. Journal of Pharmaceutical Sciences, 1996, 85, 1035-1043.	3.3	24

#	Article	IF	Citations
37	PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice. International Journal of Pharmaceutics, 2014, 465, 228-238.	5.2	23
38	FcRn Expression in Wildtype Mice, Transgenic Mice, and in Human Tissues. Biomolecules, 2018, 8, 115.	4.0	23
39	Application of pharmacodynamic modeling for designing time-variant dosing regimens to overcome nitroglycerin tolerance in experimental heart failure. Pharmaceutical Research, 1997, 14, 1140-1145.	3.5	22
40	Pharmacokinetic/Pharmacodynamic Modeling of IVIG Effects in a Murine Model of Immune Thrombocytopenia. Journal of Pharmaceutical Sciences, 2007, 96, 1625-1637.	3.3	22
41	High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 816, 183-192.	2.3	20
42	Development and Validation of an Enzyme Linked Immunosorbent Assay for the Quantification of Carcinoembryonic Antigen in Mouse Plasma. Journal of Immunoassay and Immunochemistry, 2009, 30, 418-427.	1.1	19
43	Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effects of FcRn Inhibitors in Mice, Rats, and Monkeys. Journal of Pharmaceutical Sciences, 2019, 108, 701-713.	3.3	18
44	High‐Affinity Rabbit Antibodies Directed Against Methotrexate: Production, Purification, Characterization, and Pharmacokinetics in the Rat. Journal of Pharmaceutical Sciences, 1995, 84, 2-6.	3.3	16
45	Target mediated disposition of T84.66, a monoclonal anti-CEA antibody. MAbs, 2010, 2, 67-72.	5.2	16
46	Strategies to enhance monoclonal antibody uptake and distribution in solid tumors. Cancer Biology and Medicine, 2021, 18, 649-664.	3.0	16
47	Antibody Dependent Enhancement of *Acinetobacter baumannii* Infection in a Mouse Pneumonia Model. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 475-489.	2.5	15
48	Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice. Journal of Pharmacokinetics and Pharmacodynamics, 2007, 34, 829-847.	1.8	14
49	Physiologically based pharmacokinetic model for topotecan in mice. Journal of Pharmacokinetics and Pharmacodynamics, 2011, 38, 121-142.	1.8	14
50	Application of a catenary PBPK model to predict the disposition of â€œcatch and releaseâ€•anti-PCSK9 antibodies. International Journal of Pharmaceutics, 2016, 505, 69-78.	5.2	14
51	Application of knockout mouse models to investigate the influence of FcÎ³R on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody. International Journal of Pharmaceutics, 2013, 444, 185-192.	5.2	13
52	Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer. AAPS Journal, 2016, 18, 923-932.	4.4	12
53	â€œCatch-and-Releaseâ€•Anti-Carcinoembryonic Antigen Monoclonal Antibody Leads to Greater Plasma and Tumor Exposure in a Mouse Model of Colorectal Cancer. Journal of Pharmacology and Experimental Therapeutics, 2018, 366, 205-219.	2.5	12
54	Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Predicting the Effects of Anti-FcRn Therapy on the Disposition of Endogenous IgG in Humans. Journal of Pharmaceutical Sciences, 2019, 108, 714-724.	3.3	12

#	ARTICLE	IF	CITATIONS
55	Investigation of the Influence of Nephropathy on Monoclonal Antibody Disposition: A Pharmacokinetic Study in a Mouse Model of Diabetic Nephropathy. Pharmaceutical Research, 2014, 31, 1185-1193.	3.5	11
56	Physiologically-based modeling to predict the clinical behavior of monoclonal antibodies directed against lymphocyte antigens. MAbs, 2017, 9, 297-306.	5.2	11
57	Development and Evaluation of Competitive Inhibitors of Trastuzumab-HER2 Binding to Bypass the Binding-Site Barrier. Frontiers in Pharmacology, 2022, 13, 837744.	3.5	9
58	Predicting the effects of 8C2, a monoclonal anti-topotecan antibody, on plasma and tissue disposition of topotecan. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 55-69.	1.8	8
59	Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopenia. AAPS Journal, 2005, 7, E895-E902.	4.4	7
60	Application of Anti-Methotrexate Fab Fragments for the Optimization of Intraperitoneal Methotrexate Therapy in a Murine Model of Peritoneal Cancer. Journal of Pharmaceutical Sciences, 2005, 94, 1957-1964.	3.3	7
61	AN ELISA FOR QUANTIFICATION OF T84.66, A MONOCLONAL ANTI-CEA ANTIBODY, IN MOUSE PLASMA. Journal of Immunoassay and Immunochemistry, 2009, 31, 1-9.	1.1	7
62	High-Throughput, Sensitive LC-MS Quantification of Biotherapeutics and Biomarkers Using Antibody-Free, Peptide-Level, Multiple-Mechanism Enrichment via Strategic Regulation of pH and Ionic and Solvent Strengths. Analytical Chemistry, 2019, 91, 3475-3483.	6.5	7
63	Development and Validation of Enzyme‐Linked Immunosorbent Assays for Quantification of Anti‐Methotrexate IgG and Fab in Mouse and Rat Plasma. Journal of Immunoassay and Immunochemistry, 2004, 25, 335-344.	1.1	6
64	Physiologically Based Modeling of the Pharmacokinetics of â€œCatch-and-Releaseâ€• Anti-Carcinoembryonic Antigen Monoclonal Antibodies in Colorectal Cancer Xenograft Mouse Models. Journal of Pharmaceutical Sciences, 2019, 108, 674-691.	3.3	6
65	The impact of sialylation linkage‐type on the pharmacokinetics of recombinant butyrylcholinesterases. Biotechnology and Bioengineering, 2020, 117, 157-166.	3.3	5
66	Development and Characterization of High-Affinity Anti-Topotecan IgG and Fab Fragments. , 0, , 835-850.		4
67	Investigation of the Influence of Protein-Losing Enteropathy on Monoclonal Antibody Pharmacokinetics in Mice. AAPS Journal, 2017, 19, 1791-1803.	4.4	4
68	Development and validation of an enzyme-linked immunosorbent assay for the quantification of gelonin in mouse plasma. Journal of Immunoassay and Immunochemistry, 2016, 37, 611-622.	1.1	3
69	Targeted Delivery of Endosomal Escape Peptides to Enhance Immunotoxin Potency and Anti-cancer Efficacy. AAPS Journal, 2022, 24, 47.	4.4	2
70	Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition. International Journal of Molecular Sciences, 2022, 23, 679.	4.1	0